Ketocon

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ketocon

Property Description
Active ingredient Ketoconazole (INN)
Form Oral Tablet, Topical Cream, Shampoo, Solution
Pharmacological class Antifungal Agent, Azole Derivative
Common purpose Control and eliminate fungal proliferation
Origin Synthetic compound (Imidazole subclass)

What Type of Medicine is Ketocon (Ketoconazole)?

Ketocon is a medication defined by its active ingredient, Ketoconazole, which is classified as a synthetic broad-spectrum antifungal agent and azole derivative. This classification identifies it as a single-ingredient pharmaceutical used to control the growth and spread of various harmful fungi and yeasts.

Ketoconazole is chemically synthesized and belongs specifically to the imidazole subclass of azoles. Compared to some later-generation azoles, Ketoconazole holds a unique position, being one of the first synthetic compounds in its class to achieve widespread clinical use. Ketoconazole remains a valuable agent in treating fungal infections, particularly those affecting the skin and, in specific contexts, those that are systemic.

The Composition and Available Forms of Ketoconazole

The primary active component is Ketoconazole, which is designed for flexible delivery via both localized and systemic routes of administration. Ketoconazole is supplied in several distinct dosage forms, including the oral tablet for internal (systemic) use and various topical preparations such as cream, shampoo, and solution for external (cutaneous) administration.

This range of forms enables the treatment of fungal proliferation whether it manifests superficially on the skin or requires internal action. Topical products integrate the active ingredient into bases like emulsified cream or specialized cleansing vehicles, while the oral tablet uses excipients to ensure stability and proper systemic delivery.

How Ketoconazole Works Against Fungi (General Principle)

The foundational principle by which Ketoconazole achieves its effect is through the targeted disruption of the fungal cell membrane. It functions as a specific inhibitor of the cytochrome P450 14alpha-demethylase enzyme, which is critical in the biosynthesis of ergosterol. By blocking the synthesis of this essential molecule, Ketoconazole impairs the fungal cell's structural integrity, which ultimately leads to both fungistatic (growth-stopping) and fungicidal (cell-killing) action against the pathogen.

Regulatory References

  1. Read more at StatPearls (NIH)
  2. FDA Drug Labels (DailyMed)

What side effects are possible with Ketocon?

Possible Side Effects and Safety Information

The regulatory safety profile for Ketoconazole varies significantly between the systemic oral tablet and the localized topical preparations (cream, shampoo, solution).

Serious Systemic Safety Considerations (Oral Tablet)

Official regulatory documents highlight the potential for serious hepatotoxicity (liver injury), which may result in fatal outcomes or require liver transplantation. This risk is present regardless of whether the oral tablet is used for short or long treatment durations. The oral formulation is also associated with adrenal insufficiency (reduced corticosteroid production), and carries a risk for QT interval prolongation and severe ventricular dysrhythmias when co-administered with certain drugs.

Classification Adverse Reaction Examples
Common (Oral) Nausea, Vomiting, Abdominal Pain, Application Site Burning (Topical)
Serious (Oral) Hepatotoxicity, Adrenal Insufficiency, Anaphylaxis, QT Prolongation

Local Reactions and Safety Restrictions

For topical forms, adverse reactions are primarily confined to the site of application and are most frequently classified as common. These typically include local effects such as a burning sensation, pruritus (itching), and erythema (redness) of the skin.

Safety labeling includes explicit constraints on the oral tablet: it is contraindicated in patients with underlying acute or chronic liver disease. Furthermore, the safety and effectiveness of many forms of Ketoconazole have not been established for use in pediatric patients.

Overdose and Emergency Response

The official regulatory documents describe the profile of an overdose of oral Ketoconazole by detailing both acute manifestations and severe physiological risks, along with required emergency procedures.

Documented Overdose Manifestations

Acute overdose of the oral tablet form may present with symptoms such as nausea and vomiting. High systemic exposure has been associated with signs of acute liver injury, which may include fatigue, anorexia, and jaundice. Overdose can also lead to the development of adrenal insufficiency.

Severe Outcomes and Emergency Actions

Overdose is classified as a condition that can result in serious hepatotoxicity, potentially requiring liver transplantation or leading to a fatal outcome. The potential for QT prolongation and resultant ventricular dysrhythmias is also documented as a severe risk.

In the event of a suspected overdose, it is mandated that immediate medical attention be sought.

Supportive Management and Monitoring

  • Treatment Approach: Management of overdose is limited to symptomatic and supportive treatment, as no specific antidote is known.
  • Procedural Steps: For acute oral ingestion, gastric lavage or administration of activated charcoal may be performed, generally if the intervention occurs within the first hour of ingestion.
  • Monitoring Requirements: Close hospital monitoring is required for assessment of cardiac, fluid, and electrolyte status, including regular liver function tests to monitor for potential hepatic damage. Individuals with pre-existing hepatic impairment may be more susceptible to severe consequences.

Therapeutic Uses of Ketocon

What Ketocon Treats: Main Uses and Benefits

Ketoconazole is commonly used to help manage symptoms related to inflammatory or irritative states caused by cutaneous fungal and yeast infections, targeting conditions such as the tineas (Tinea corporis, pedis, cruris) and the symptoms of seborrheic dermatitis and dandruff associated with Malassezia overgrowth.

The medicine is considered relevant for situations where symptoms may intensify temporarily, providing support that helps ease the overall symptom burden associated with fungal proliferation. For conditions presenting with systemic discomfort, such as serious, extensive fungal diseases like Histoplasmosis or Blastomycosis, it is applied internally when supportive symptom management is appropriate. In specialized clinical contexts, it may also assist in managing symptoms related to systemic imbalance associated with excessive steroid hormone production.

“The primary benefit is the reduction of bothersome symptoms like scaling, redness, and persistent itching, which contributes to improved comfort during periods of heightened symptoms.”

This medication is relevant across therapeutic areas where additional symptomatic support is needed to address groups of symptoms that may become disruptive or interfere with daily comfort.

Quick Fact: Relief for Itching and Scaling
Ketoconazole is generally used to help address the pronounced scaling, redness, and intense itching commonly seen in fungal skin and scalp conditions, supporting patients during these episodes of heightened discomfort.

Regulatory References

  1. NIH StatPearls overview of Antifungal Agents

Eligibility and Restrictions for Use

Who Can and Cannot Use Ketoconazole

Eligibility for ketoconazole use is highly dependent on the formulation (oral tablet vs. topical cream/shampoo) and the patient's existing health profile, especially concerning the liver.


Contraindicated Populations (Must Not Use)

Classification Exclusion Criterion Formulation
Liver Status Patients with pre-existing acute or chronic liver disease Oral Tablet Only
Hypersensitivity Patients with a known allergy to ketoconazole or any component of the specific formulation All Forms
Drug Interactions Patients taking specific medications that are strictly prohibited due to risk of life-threatening interactions (e.g., specific drugs that prolong the QT interval, certain statins, ergot alkaloids) Oral Tablet Only

Restricted or Limited Use

Oral ketoconazole is reserved as a second-line or alternative therapy for severe systemic fungal infections when other treatments have failed or are not tolerated. Its use requires careful monitoring and patient selection.

Age Restrictions:

  • Oral Tablet: Safety and effectiveness have not been established in children under 2 years of age.
  • Topical Forms: Use is often restricted in children, with some topical formulations (e.g., 2% shampoo) having an age floor of 12 years of age established for safety and effectiveness.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ketoconazole oral tablets possess an officially documented interaction profile primarily governed by its potent effect on metabolic pathways. The medicine is classified as a strong inhibitor of the CYP3A4 enzyme and P-glycoprotein transporter, which leads to a clinically significant increase in the plasma concentrations of many co-administered medicines, as stated in regulatory documents.

Formal Interaction Restrictions

Regulatory authorities formally contraindicate co-administration with numerous drugs due to the risk of severe toxicity, including life-threatening adverse reactions such as QTc prolongation and rhabdomyolysis. Medicines listed as contraindicated include oral triazolam, midazolam, lovastatin, simvastatin, dofetilide, quinidine, and ergot alkaloids (e.g., ergotamine).

Separately, the absorption of Ketoconazole is highly dependent on an acidic environment. Substances that reduce gastric acidity, such as antacids, H2-blockers, and Proton Pump Inhibitors (PPIs), cause a reduction in Ketoconazole exposure.

Substance Category Required Regulatory Action
Gastric Acid Reducers Mandatory dose separation or co-administration with an acidic beverage
Alcohol Avoidance due to increased risk of liver damage
CYP3A4 Inducers (e.g., rifampin) Not recommended due to reduced Ketoconazole blood levels

Ketoconazole is contraindicated in patients with acute or chronic liver disease. The official labeling also cites specific interaction constraints for certain populations, such as the contraindication of colchicine co-administration in patients with renal impairment.

Mechanism of Action

Blocking the Fungal Ergosterol Pathway

Ketoconazole initiates its effect by acting as an inhibitor of the fungal enzyme Cytochrome P450 14 alpha-demethylase (CYP51). By chemically binding to the enzyme's active site, the drug halts the synthesis of ergosterol, the key structural sterol essential for maintaining the integrity of the fungal cell membrane.

Causing Cell Membrane Failure

The lack of ergosterol and the concurrent accumulation of abnormal, toxic sterols severely compromise the fungal cell membrane's stability and function. This structural failure causes the membrane to become abnormally permeable and rigid, leading to the leakage of vital cellular contents and the disruption of essential membrane-bound processes. This cascading sequence of events results in fungistatic (inhibition of proliferation) and fungicidal (induction of cell death) consequences at the cellular level.

Specificity and Limitations

While primarily targeting the fungal 14alpha-DM, Ketoconazole’s structure gives it the inherent capacity to interact with certain mammalian Cytochrome P450 enzymes. Furthermore, the mechanism can be functionally constrained when fungi develop resistance, typically through genetic mutations in the CYP51 target or by increasing the activity of cellular efflux pumps that increase the transport of the drug out of the cell .

Dosage and Administration Information

How to Use Ketoconazole: Official Administration Guidelines

The usage of Ketoconazole is defined by its dosage form and intended route. The medicine is administered via the oral route (tablet) for systemic conditions and via topical preparations (cream, foam, shampoo, gel) for localized skin and scalp applications.

Oral Dosing and Conditions

Application Standard Adult Regimen Special Condition
Systemic Fungal Infections Initial mathbf200 mg once daily (may increase to 400 mg if needed). Must be taken with a meal for optimal absorption.
Cushing's Syndrome Initial mathbf400 mg to mathbf600 mg/day in mathbf2 or 3 divided doses, titrated up to 1,200 mg/day. Requires supervision by a specialist physician.

For pediatric patients mathbfge 2 years with systemic fungal infections, the dose is determined based on body weight, typically mathbf3.3 to 6.6 mg/kg/day. Dose adjustments are generally not recommended for older adults or patients with renal impairment.

Topical Administration

Topical preparations are applied directly to the skin or scalp following specific schedules. For cutaneous infections like tinea corporis or candidiasis, 2% cream is applied once daily for mathbf2 weeks. Tinea pedis (athlete's foot) requires a longer course of mathbf6 weeks. For seborrheic dermatitis, the 2% cream or foam is applied twice daily for mathbf4 weeks. Shampoo (often 1% or 2%) requires the user to wet the hair, lather, leave the product on the affected area for mathbf5 minutes, and then rinse thoroughly.

Regardless of the form, treatment must be continued for the full duration prescribed by the physician.

Recent Clinical Evidence

Research evidence / Overview of studies for Ketocon

Evidence for Use in Systemic Fungal Infections

This section describes the nature of the research available, including the older randomized controlled trials (RCTs) and observational studies that examined the systemic (internal) use of Ketocon for conditions characterized by functional limitations, such as Blastomycosis and Histoplasmosis. These initial studies were often conducted during periods of increased symptom activity and monitored patient-related outcomes and long-term status.

The research examined outcomes in adult patients with serious, extensive endemic mycoses. Early trials monitored patient cohorts over several months and described patterns of symptom change and mycological status in those receiving sustained treatment. Regulatory reviews describe limitations in this evidence base compared to research for newer agents, and long-term effects are not fully established based on the available data.


Evidence for Use in Superficial Skin and Yeast Infections

This part outlines the clinical evidence base for topical forms (cream, solution), primarily focusing on double-blind trials and meta-analyses that have examined its use for Tinea infections and Cutaneous Candidiasis. This research explores short-term symptom changes in conditions marked by functional limitations and outcomes linked to inflammatory or irritative states.

The research examined patient-reported outcomes describing perceived discomfort and the objective measure of mycological cure (clearing of the fungus). Short-term RCTs examined outcomes for signs such as redness and peeling, and documented measured change when the topical product was evaluated compared to a non-active vehicle base. However, the follow-up durations were limited in many studies, meaning comparative evidence is lacking for many currently available alternative topical treatments.


Evidence Gaps and Areas of Uncertainty

This final section synthesizes the key limitations noted in the regulatory and scientific literature. For topical use, the follow-up durations were limited, meaning long-term effects are not fully established for sustained symptom clearance. For all studied uses, the results apply only to the populations studied, and data for certain groups remain insufficient. This research highlights what is known — and what is still uncertain — about the evidence landscape for Ketoconazole.

Key Studies & References

  1. WHO Expert Committee on the Selection and Use of Essential Medicines: Application for inclusion of Ketoconazole in the WHO Model List (Cushing Syndrome)

Frequently Asked Questions (FAQ)

Common questions about Ketocon (FAQ)

Q: What is the main reason doctors prescribe Ketocon?

A: According to regulatory documents, the oral tablet form of Ketoconazole is indicated for treating specific severe systemic fungal infections, such as blastomycosis and histoplasmosis. This use is generally reserved for patients who have not responded to or cannot tolerate other available treatments. The medication helps control the growth and spread of these internal fungi.

Q: How quickly does Ketocon usually start working?

A: Studies and official information indicate that for certain infections, patients may notice clinical improvement and symptom relief within the first week of starting therapy. However, it is necessary to adhere to the full duration of therapy prescribed by a healthcare provider, even if symptoms begin to clear quickly.

Q: Are there special warnings about Ketocon for older adults?

A: Official regulatory information states that there is no specific information available concerning the relationship of age to the effects of Ketoconazole in geriatric patients (older adults). Dose adjustments are generally not recommended for this group, but individual medical circumstances are always necessary for consideration.

Q: Are there any specific groups of people who are more likely to experience side effects from Ketocon?

A: Official product information identifies certain groups as potentially being at a higher risk of adverse effects. These include patients with conditions such as low stomach acid (achlorhydria), pre-existing adrenal problems, or certain types of heart disease or rhythm problems.

Q: Do common foods or drinks interfere with Ketocon?

A: Regulatory guidance suggests that the consumption of grapefruit or grapefruit juice is subject to restriction or limitation, as noted in the guidance. This is because specific substances in grapefruit may interact with the medicine's metabolism, leading to increased concentrations in the blood.

Q: What research has been done on Ketocon use in children?

A: According to official documentation, Ketoconazole tablets have not been systematically studied in children of any age. Furthermore, safety and effectiveness have not been established for use in pediatric patients younger than two years old.

Q: Can Ketocon be used by people with kidney problems?

A: Regulatory labeling indicates that specific dosage modifications are not typically provided for patients experiencing renal impairment (kidney problems). The overall safety profile and constraints remain subject to assessment by a healthcare professional.

Q: What is the meaning of the Boxed Warning sometimes associated with Ketocon?

A: The Boxed Warning is a regulatory notice used to highlight the most serious potential risks of a medication. For Ketoconazole, this warning alerts patients and providers to the potential for severe hepatotoxicity (liver damage) and the risk of QT prolongation, which may lead to life-threatening heart rhythm problems.

Q: Are there specific food items that must be avoided when taking Ketocon?

A: Official patient information indicates that grapefruit and grapefruit juice are specific items that are listed as restricted or limited while taking the medication. This precaution is related to the potential for interaction that can alter the drug's levels in the body.

Q: What is the recommended approach if I think I'm having a side effect from Ketocon?

A: Regulatory guidance indicates that patients should immediately report any signs of possible liver dysfunction to a healthcare professional. These signs may include symptoms such as unusual fatigue, loss of appetite, nausea, vomiting, or dark urine, so that appropriate medical assessment and testing can be conducted.

Q: Is Ketocon the same as other medicines for the same condition?

A: Ketoconazole is classified as an azole derivative antifungal, specifically belonging to the imidazole subclass. While it is used for certain fungal infections, authoritative sources describe that newer triazole agents are often used instead.

Q: Are there any widely known natural products that interact with Ketocon?

A: Regulatory guidance identifies grapefruit and supplements containing grapefruit extract as substances that are listed as restricted or limited due to potential drug interactions. Official labeling requires disclosure to the healthcare provider of all supplements, vitamins, and natural products being taken.

Q: Is it true that Ketocon can cause unusual changes in vision?

A: According to official product monographs, visual disturbances are among the reported side effects of Ketoconazole. Visual disturbances are reported and are a matter for consultation with a healthcare professional.

Q: Why is Ketocon not generally recommended for pregnant women?

A: Official regulatory documents classify the medicine as Pregnancy Category C. This means there are no adequate and well-controlled studies in pregnant women. The drug is reserved for use during pregnancy only when the potential benefit is judged to outweigh the potential risk.

Q: What happens if Ketocon is suddenly stopped?

A: Regulatory guidance advises against stopping the medication without first consulting a healthcare professional. Stopping the medication too soon may prevent the underlying infection from clearing up completely, which can lead to a recurrence of the fungal condition.

Q: Is Ketocon generally safe for people who drive or operate machinery?

A: Possible side effects, including dizziness and drowsiness, are reported in the official safety information. These effects are reported and should be considered by the patient when deciding to drive or operate machinery.

Q: Can Ketocon affect the results of blood tests?

A: Yes, the medicine can affect certain blood test results. Because of the risk of hepatotoxicity, blood tests are used to monitor liver function (such as ALT and AST levels), and cortisol levels are also monitored in some patients.

Q: How is Ketocon usually cleared out of the body?

A: Official pharmacological data indicates that more than 95% of Ketoconazole is eliminated from the body through hepatic metabolism, which means it is processed and broken down by the liver. Only a very small fraction is excreted unchanged through urine.

Q: What happens if a user misses a dose of Ketocon?

A: If a dose is missed, regulatory guidance suggests taking it as soon as it is remembered, unless it is almost time for the next scheduled dose. In that case, the missed dose is intended to be skipped, and patients are directed not to take double or extra doses to compensate.

Q: Is it common for Ketocon users to report fatigue?

A: Tiredness and weakness are reported as possible side effects in official product information. Furthermore, unusual fatigue is noted as a symptom identified as one requiring professional evaluation by a healthcare provider, as it may be a sign of potential liver dysfunction.

Q: Does using Ketocon change your sensitivity to the sun?

A: Sensitivity to light, known as photosensitivity, is a reported side effect of the medicine. This potential reaction is noted in the medication's safety information.

Q: Is Ketocon a medicine that needs to be taken at a specific time of day?

A: Official administration guidelines state that the medicine is mandated to be taken with food to ensure proper dissolution and absorption into the body. There is no general requirement that the medicine must be taken at a specific time of day, such as morning or evening.

Q: Is Ketocon known to affect birth control pills?

A: Ketoconazole is known to affect certain metabolic enzymes and may increase the plasma concentrations of hormonal contraceptives (birth control pills). This potential interaction is noted in the medicine's official label.

Q: Can Ketocon be taken with multivitamins?

A: Official patient counseling materials emphasize the need to disclose to the healthcare provider all other medications being taken, including multivitamins and herbal supplements. This disclosure is necessary because interactions can occur between Ketoconazole and other products.

Q: Can Ketocon be crushed or broken if swallowing is difficult?

A: While specific instructions for crushing are not generally provided, studies examining special populations have shown that measurable blood concentrations of the drug can be achieved when administered as a crushed tablet. The clinical decision regarding dose alteration rests with the prescribing physician.

How should Ketocon be stored and disposed of?

Ketoconazole must be stored according to official regulatory specifications to maintain its stability and effectiveness.

Dosage Form Temperature Requirement Environmental Protection
Oral Tablet Controlled Room Temp (20 C to 25 C) Protect from moisture and light
Topical Cream/Gel Generally leq 30 C Do not freeze; protect from light
Topical Foam 20 C to 25 C Protect from heat and direct sunlight

Oral tablets must be dispensed and kept in a tight, light-resistant container. The pressurized topical foam container includes warnings that the contents are flammable and must not be exposed to heat, stored above 49 C (120 F), punctured, or incinerated. All formulations of Ketoconazole must be kept out of the sight and reach of children. Unused or expired medication should be disposed of according to local regulations and should not be flushed down the toilet or poured down a drain unless specifically instructed by the accompanying drug labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ketocon found in:

A-Z Index: